For decades, calcium has been the body’s universal alarm signal — flooding into cells to trigger muscle contractions, spark nerve impulses, and mobilize immune responses. Now a study from Northeast Normal University in China suggests that this same calcium signal, when it goes chronically haywire in aging tissues, may be actively driving the cellular deterioration we call getting old.
The paper, published in Nature Communications in 2026, begins with a deceptively simple observation: in mice engineered to age at ten times the normal rate (a model of the rare premature aging disease Hutchinson-Gilford Progeria Syndrome, or HGPS), calcium is leaking out of the endoplasmic reticulum — the cell’s internal calcium storage tank — and flooding the cytoplasm. This finding alone is not new. What the team went on to show is exactly how that calcium spill translates into biological aging, step by molecular step, and how blocking it with a drug that costs pennies per dose can meaningfully extend lifespan.
The mechanism is a protein called S100A6, a calcium-binding protein that quietly patrols the nucleus in healthy young cells but migrates to the cytoplasm when intracellular calcium rises. Once in the cytoplasm, S100A6 moonlights as a hitman: it recruits a second protein, CacyBP, and together they tag PARP1 — a critical DNA repair enzyme — for destruction by the cell’s proteasome garbage disposal system. With PARP1 gone, DNA damage accumulates. Broken chromosome fragments spill into the cytoplasm (cytoplasmic chromatin fragments, or CCF). Those fragments trigger the cGAS-STING innate immune pathway, which fires up NF-kB and floods surrounding tissue with inflammatory cytokines — a state known as the SASP (senescence-associated secretory phenotype). In short: leaked calcium → lost DNA repair → chronic inflammation → organ aging. The researchers confirmed this same S100A6 cytoplasmic accumulation in skin and stem cells from humans in their 70s, 80s, and 90s, not just in the engineered mouse model.
Their therapeutic solution was unexpectedly practical. Mianserin (MIA) is a tetracyclic antidepressant approved for clinical use since the 1970s, common in Europe and Asia. It had already been shown to extend lifespan in the roundworm C. elegans. Here, by blocking serotonin receptors HTR2B and HTR2C — which activate the very IP3 receptor channel that leaks calcium — mianserin effectively plugs the calcium drain. In progeroid mice, 10 mg/kg MIA every other day extended median survival by 27.89%. In normal, naturally aging C57BL/6J male mice started on the drug at 20 months of age, median survival extended from 823 days to 967 days — a gain of 144 days, or 17.5%. Maximum lifespan jumped from 869 to 1,055 days.
The study is a pre-publication article in press as of June 2026. The mechanistic story is unusually complete for a longevity paper, with human cell validation across multiple aging models. Whether mianserin works through the same mechanism in humans remains to be proven.
Actionable Insights
The paper’s central finding is that chronic elevation of intracellular calcium — measurable in aging tissues and correlated with S100A6 cytoplasmic accumulation — drives a discrete, druggable pathway toward senescence and organ dysfunction. Several take-home messages emerge:
First, S100A6 cytoplasmic localization may become a useful biomarker for chronic cellular senescence, distinguishable from the nuclear S100A6 seen in cancer. Its presence in aged human skin biopsies (>70 years old) and elderly mesenchymal stem cells suggests translational relevance.
Second, PARP1 restoration may matter more than PARP1 inhibition in aging contexts. The field has largely focused on PARP1 inhibitors to boost NAD+ via the salvage pathway. This paper suggests the opposite problem in natural aging: PARP1 is being degraded, not just exhausted. Approaches that preserve PARP1 protein stability (reducing calcium-driven S100A6 accumulation) may synergize with NAD+ precursor strategies.
Third, for the lifespan effect in naturally aging mice, the intervention extended median survival by 17.5% (+144 days) and maximum lifespan by 21.4% (+186 days). To contextualize the magnitude: rapamycin, the gold-standard mouse longevity drug, typically extends median survival by 10-23% in various studies. Mianserin’s effect size in this single study is competitive with rapamycin, though this has not been replicated or confirmed in a rigorous multi-site trial. The cardiac, pulmonary, and muscular functional improvements in both progeroid and aged mice suggest genuine healthspan benefits, not merely lifespan extension.
Fourth, mianserin is clinically approved, inexpensive, and has a 50-year safety record. For those tracking their intracellular calcium or inflammaging markers (hs-CRP, SASP cytokines), this paper provides a new mechanistic rationale for calcium management as an anti-aging strategy.
The critical catch: The natural aging lifespan experiment has two serious structural problems — N-numbers are never stated in the text, and only male mice were used. The controls at 823 days median survival are also borderline short-lived by the 900-day rule, though the treated mice clearing 967 days (above the historical C57BL/6J male ceiling) partially rescues the interpretation. Also, the most important experiment — natural aging lifespan — had n=7–8 mice. That’s enough to publish in Nature Communications and get a log-rank p-value, but it’s not enough to trust the “17.5%” number as a meaningful effect size estimate. Treat it as a directional signal.
Source:
- Open Access Paper: Ameliorating calcium homeostasis improves longevity and healthspan in progeroid and naturally aged mice
- Institution: Northeast Normal University (primary); China-Japan Union Hospital of Jilin University; Second Hospital of Jilin University; Jilin Agricultural University; Bioland Laboratory, Guangzhou, China
- Country: China
- Journal: Nature Communications
- Impact Evaluation: The impact score of this journal is approximately 14.7 (2023 Journal Impact Factor), evaluated against a typical high-end range of 0-60+ for top general science journals; therefore this is a High impact journal.
